Follitropin alfa is indicated for controlled ovarian stimulation in women undergoing assisted reproductive technologies such as IVF/ICSI, and for ovulation induction in anovulatory patients. It is also used in men with hypogonadotropic hypogonadism to stimulate spermatogenesis in combination with hCG. Its key advantage is highly purified recombinant FSH with consistent potency, ensuring predictable ovarian response and precise dose adjustment. Subcutaneous administration allows flexible, patient-friendly use, while clinicians benefit from reliable follicular development and optimized cycle outcomes. In fertility centers, follitropin alfa supports individualized stimulation protocols, helping reduce cycle variability and improve success rates. Its well-established efficacy and safety profile make it a cornerstone therapy in modern reproductive medicine.